-

About

Ben leads the Genito-Urinary (GU) research program within the Gibbs Lab at WEHI. His team focuses on generating Real World Evidence (RWE) to change practice in GU cancers.

Ben is also a medical oncologist at Peter MacCallum Cancer Centre where he leads the GU medical oncology group and trials program. He is an Associate Professor at the University of Melbourne. Ben also chairs the Phase 1 Trials Group within Cancer Trials Australia and the Germ Cell Tumour group within ANZUP.

At WEHI, Ben leads multi-national registries in Prostate cancer, Urothelial cancer, Testis cancer and Kidney cancer. Data from these registries have been utilized to describe treatment patterns, identify clinical and tissue-based biomarkers and inform future research strategies. Ben has expanded the out-reach of these registries to Asia, with sites now contributing from Singapore and Korea. Ben is recognized globally for his leadership in RWE in GU cancers. Ben is also internationally recognized as an expert in testicular cancer, utilizing his RWE leadership to drive pragmatic clinical trials aimed at improving long term outcomes for testicular cancer survivors.

Ben also leads the early development of novel therapeutics in GU cancers. He is globally respected for his knowledge and expertise in early phase, first time in human clinical trials. His role within developmental therapeutics is essential in connecting scientists to clinicians and facilitating a bench to bedside and back to bench approach to cancer research.

Publications

Selected publications from A/Prof Ben Tran

Bainomugisa CK, Dasgupta P, Cameron JK, Tran B, Cramb SM, Baade PD. Spatial patterns of testicular cancer diagnosis in Australia, 2010-2019. Spatial and Spatio-temporal Epidemiology. 2025;55:10.1016/j.sste.2025.100745

Shahnam A, Hitchen N, Manoharan S, John T, Mileshkin L, Solomon B, Sandhu S, Luen SJ, Desai J, Tran B. Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies. Journal of Geriatric Oncology. 2025;16(8):10.1016/j.jgo.2025.102721

Hiong A, Lynam J, Weickhardt A, Wong S, Sengupta S, Manohar P, Wong L, Dundee P, Lawrentschuk N, Zhang AY, Anton A, Raghunath A, Gibbs P, Tran B. Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia. BJUI Compass. 2025;6(9):10.1002/bco2.70083

Aziz NA, Ng K, Alifrangis C, Tran B, Conduit C, Liow E, Ackerman C, Georgescu R, Jamal T, Relton C, Mayer E, Nicol D, Cazzaniga W, Huddart R, Reid A, Shamash J, Rajan P. Therapy de‐escalation for testicular cancer (THERATEST): A multi‐centre observational cohort feasibility study of de‐escalation therapies for good prognosis stage II germ cell tumours. BJUI Compass. 2025;6(8):10.1002/bco2.70057

Furic L, Ferreira R, Hannan K, Kusnadi E, Panov K, George A, Huglo A, Lawrence M, Tran B, Desai J, Drygin D, Haddach M, Hein N, Hannan RD. 77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial. ESMO Open. 2025;10:10.1016/j.esmoop.2025.105427

Manoharan S, Shahnam A, Hitchen N, Williams S, Zhong Y, Shaya SJ, Mweempwa A, Mileshkin L, Solomon B, Luen SJ, Desai J, Tran B. 115O PROPOSE: Predicting phase I trial fitness using patient-reported outcomes and a clinician-completed prognostic index. ESMO Open. 2025;10:10.1016/j.esmoop.2025.105468

Manoharan S, Shahnam A, Hitchen N, John T, Mileshkin L, Solomon B, Sandhu SK, Luen SJ, Desai J, Tran B. 118P Impact of age and comorbidity on safety outcomes in phase I trials participants for metastatic solid malignancies. ESMO Open. 2025;10:10.1016/j.esmoop.2025.105471

Moody SC, Fietz D, Nathaniel B, Frydenberg M, Tran B, Schuppe H, Loveland KL. Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours. Andrology. 2025;:10.1111/andr.70100

Conduit C, Bagrodia A, Hamilton RJ, Feldman DR, Tran B. Optimal Management of Stage II Seminoma: Preventing Harm While Preserving Cure.JCO Oncology Practice. 2025;:10.1200/op-25-00252

Williams C, Inderjeeth A-J, Hong W, McKenzie J, Anton A, Weickhardt A, Wong S, Shapiro J, Parente P, Goh J, Torres J, Smith A, Joshua A, Brown S, Steer C, Johns J, Gibbs P, Tran B, Azad AA. Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study. Clinical Genitourinary Cancer. 2025;23(3):10.1016/j.clgc.2025.102345

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.